These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 15229633

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.
    Pramono ZA, Wee KB, Wang JL, Chen YJ, Xiong QB, Lai PS, Yee WC.
    Hum Gene Ther; 2012 Jul; 23(7):781-90. PubMed ID: 22486275
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
    Maruyama R, Aoki Y, Takeda S, Yokota T.
    Methods Mol Biol; 2018 Jul; 1828():365-379. PubMed ID: 30171554
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications.
    Aartsma-Rus A, van Ommen GJ.
    RNA; 2007 Oct; 13(10):1609-24. PubMed ID: 17684229
    [Abstract] [Full Text] [Related]

  • 49. Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes.
    Echigoya Y, Yokota T.
    Methods Mol Biol; 2023 Oct; 2587():125-139. PubMed ID: 36401027
    [Abstract] [Full Text] [Related]

  • 50. Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.
    Verhaart IE, Heemskerk H, Karnaoukh TG, Kolfschoten IG, Vroon A, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.
    Hum Gene Ther; 2012 Mar; 23(3):262-73. PubMed ID: 22017442
    [Abstract] [Full Text] [Related]

  • 51. Exon-skipping events in candidates for clinical trials of morpholino.
    Nakano S, Ozasa S, Yoshioka K, Fujii I, Mitsui K, Nomura K, Kosuge H, Endo F, Matsukura M, Kimura S.
    Pediatr Int; 2011 Aug; 53(4):524-9. PubMed ID: 21342350
    [Abstract] [Full Text] [Related]

  • 52. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
    Matsuo M.
    IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
    [Abstract] [Full Text] [Related]

  • 53. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, Janghra N, Tasca G, Guglieri M, Barresi R, Armaroli A, Ferlini A, Bushby K, Straub V, Ricci E, Sewry C, Morgan J, Muntoni F.
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [Abstract] [Full Text] [Related]

  • 54. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
    Wang Q, Yin H, Camelliti P, Betts C, Moulton H, Lee H, Saleh AF, Gait MJ, Wood MJ.
    J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
    [Abstract] [Full Text] [Related]

  • 55. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S, Mizobe Y, Takizawa H, Hara Y, Yokota T, Takeda S, Aoki Y.
    Methods Mol Biol; 2018 Apr; 1687():123-141. PubMed ID: 29067660
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
    Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD.
    Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
    [Abstract] [Full Text] [Related]

  • 59. Contributions of Japanese patients to development of antisense therapy for DMD.
    Matsuo M, Takeshima Y, Nishio H.
    Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
    [Abstract] [Full Text] [Related]

  • 60. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
    Yin H, Lu Q, Wood M.
    Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.